Funded equally by LUNGevity Foundation and the American Lung Association National Office
Nouri Neamati, PhD
University of Southern California
Los Angeles
Dr. Neamati is carrying out in-depth preclinical studies on a prototype compound, SC21. He is studying where the SC21 compound travels in the body, its safety, and its effectiveness in non-small cell lung cancer (NSCLC), with the ultimate goal of bringing SC21 to the clinic.